Cargando…

Survival in patients with synchronous liver metastases in central and northern Denmark, 1998 to 2009

OBJECTIVE: In Denmark, the strategy for treatment of cancer with metastases to the liver has changed dramatically during the period 1998 to 2009, when multidisciplinary care and a number of new treatments were introduced. We therefore examined the changes in survival in Danish patients with colorect...

Descripción completa

Detalles Bibliográficos
Autores principales: Høyer, Morten, Erichsen, Rune, Gandrup, Per, Nørgaard, Mette, Jacobsen, Jacob Bonde
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144773/
https://www.ncbi.nlm.nih.gov/pubmed/21814465
http://dx.doi.org/10.2147/CLEP.S20613
_version_ 1782209036871008256
author Høyer, Morten
Erichsen, Rune
Gandrup, Per
Nørgaard, Mette
Jacobsen, Jacob Bonde
author_facet Høyer, Morten
Erichsen, Rune
Gandrup, Per
Nørgaard, Mette
Jacobsen, Jacob Bonde
author_sort Høyer, Morten
collection PubMed
description OBJECTIVE: In Denmark, the strategy for treatment of cancer with metastases to the liver has changed dramatically during the period 1998 to 2009, when multidisciplinary care and a number of new treatments were introduced. We therefore examined the changes in survival in Danish patients with colorectal carcinoma (CRC) or other solid tumors (non-CRC) who had liver metastases at time of diagnosis. STUDY DESIGN AND METHODS: We included patients diagnosed with liver metastases synchronous with a primary cancer (ie, a solid cancer diagnosed at the same date or within 60 days after liver metastasis diagnosis) during the period 1998 to 2009 identified through the Danish National Registry of Patients. We followed those who survived for more than 60 days in a survival analysis (n = 1021). Survival and mortality rate ratio (MRR) at 1, 3, and 5 years stratified by year of diagnosis were estimated using Cox proportional hazards regression analysis. RESULTS: In the total study population of 1021 patients, 541 patients had a primary CRC and 480 patients non-CRC. Overall, the 5-year survival improved from 3% (95% confidence interval [CI]: 1%–6%) in 1998–2000 to 10% (95% CI: 6%–14%) in 2007 to 2009 (predicted value). The 5-year survival for CRC-patients improved from 1% (95% CI: 0%–5%) to 11% (95% CI: 6%–18%) whereas survival for non-CRC patients only increased from 5% (95% CI: 1%–10%) to 8% (95% CI: 4%–14%). CONCLUSION: We observed improved survival in patients with liver metastases in a time period characterized by introduction of a structured multidisciplinary care and improved treatment options. The survival gain was most prominent for CRC-patients.
format Online
Article
Text
id pubmed-3144773
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-31447732011-08-03 Survival in patients with synchronous liver metastases in central and northern Denmark, 1998 to 2009 Høyer, Morten Erichsen, Rune Gandrup, Per Nørgaard, Mette Jacobsen, Jacob Bonde Clin Epidemiol Original Research OBJECTIVE: In Denmark, the strategy for treatment of cancer with metastases to the liver has changed dramatically during the period 1998 to 2009, when multidisciplinary care and a number of new treatments were introduced. We therefore examined the changes in survival in Danish patients with colorectal carcinoma (CRC) or other solid tumors (non-CRC) who had liver metastases at time of diagnosis. STUDY DESIGN AND METHODS: We included patients diagnosed with liver metastases synchronous with a primary cancer (ie, a solid cancer diagnosed at the same date or within 60 days after liver metastasis diagnosis) during the period 1998 to 2009 identified through the Danish National Registry of Patients. We followed those who survived for more than 60 days in a survival analysis (n = 1021). Survival and mortality rate ratio (MRR) at 1, 3, and 5 years stratified by year of diagnosis were estimated using Cox proportional hazards regression analysis. RESULTS: In the total study population of 1021 patients, 541 patients had a primary CRC and 480 patients non-CRC. Overall, the 5-year survival improved from 3% (95% confidence interval [CI]: 1%–6%) in 1998–2000 to 10% (95% CI: 6%–14%) in 2007 to 2009 (predicted value). The 5-year survival for CRC-patients improved from 1% (95% CI: 0%–5%) to 11% (95% CI: 6%–18%) whereas survival for non-CRC patients only increased from 5% (95% CI: 1%–10%) to 8% (95% CI: 4%–14%). CONCLUSION: We observed improved survival in patients with liver metastases in a time period characterized by introduction of a structured multidisciplinary care and improved treatment options. The survival gain was most prominent for CRC-patients. Dove Medical Press 2011-07-20 /pmc/articles/PMC3144773/ /pubmed/21814465 http://dx.doi.org/10.2147/CLEP.S20613 Text en © 2011 Høyer et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Høyer, Morten
Erichsen, Rune
Gandrup, Per
Nørgaard, Mette
Jacobsen, Jacob Bonde
Survival in patients with synchronous liver metastases in central and northern Denmark, 1998 to 2009
title Survival in patients with synchronous liver metastases in central and northern Denmark, 1998 to 2009
title_full Survival in patients with synchronous liver metastases in central and northern Denmark, 1998 to 2009
title_fullStr Survival in patients with synchronous liver metastases in central and northern Denmark, 1998 to 2009
title_full_unstemmed Survival in patients with synchronous liver metastases in central and northern Denmark, 1998 to 2009
title_short Survival in patients with synchronous liver metastases in central and northern Denmark, 1998 to 2009
title_sort survival in patients with synchronous liver metastases in central and northern denmark, 1998 to 2009
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144773/
https://www.ncbi.nlm.nih.gov/pubmed/21814465
http://dx.doi.org/10.2147/CLEP.S20613
work_keys_str_mv AT høyermorten survivalinpatientswithsynchronouslivermetastasesincentralandnortherndenmark1998to2009
AT erichsenrune survivalinpatientswithsynchronouslivermetastasesincentralandnortherndenmark1998to2009
AT gandrupper survivalinpatientswithsynchronouslivermetastasesincentralandnortherndenmark1998to2009
AT nørgaardmette survivalinpatientswithsynchronouslivermetastasesincentralandnortherndenmark1998to2009
AT jacobsenjacobbonde survivalinpatientswithsynchronouslivermetastasesincentralandnortherndenmark1998to2009